An adjuvanted vaccine against the avian influenza virus (H5N1) has been recommended for approval by an FDA advisory panel, Reuters reported last week.

Another vaccine has already been licensed for H5N1, but the newer vaccine would require much less antigen to be effective because of the presence of the adjuvant. That would make it easier to produce enough doses during an epidemic, according to the report.

Source: Reuters